https://www.live-feeds.com/feed/novartis-shareholder-calls-for-board-overhaul-following-costly-deal-setbacks-reutersContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-shareholder-calls-for-board-overhaul-following-costly-deal-setbacks-reutershttps://www.live-feeds.com/feed/novartis-shareholder-calls-for-board-overhaul-following-costly-deal-setbacks-reuters#u66816Sun, 13 Sep 2026 07:30:29 +0000Novartis shares experienced a historic drop, falling 10 percent and clocking their worst trading day in over twenty years following a succession of three drug trial failures within a single week. The most recent blow involved an RNA drug failing to meet expectations in a rare muscle disease study, specifically impacting the late-stage DM1 study for the drug del-desiran. In response to these costly development setbacks, a major shareholder has demanded a comprehensive board overhaul and shake-up, turning investor attention sharply toward past mergers and acquisitions strategy.Why it mattersThe